ARID2 and renal cell carcinoma: Given the higher frequency of ARID2 mutations in the non-RCC cohorts, we combined PBRM1 and ARID2 LOF and non-LOF mutations for individual subtype analysis, which was significant in non-small-cell lung cancers (Fig. 6a, Supplementary Table 2).